You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • OP0098 Remission and maintenance of efficacy in a phase 2b study of vobarilizumab, an anti-interleukin 6 receptor nanobody, in patients with moderate-to-severe rheumatoid arthritis despite treatment with methotrexate

Citation Tools

Article menu

Download PDFPDF

Oral Presentations
Progress in biological treatment of RA
OP0098 Remission and maintenance of efficacy in a phase 2b study of vobarilizumab, an anti-interleukin 6 receptor nanobody, in patients with moderate-to-severe rheumatoid arthritis despite treatment with methotrexate
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Dörner T, Weinblatt M, Durez P, et al
OP0098 Remission and maintenance of efficacy in a phase 2b study of vobarilizumab, an anti-interleukin 6 receptor nanobody, in patients with moderate-to-severe rheumatoid arthritis despite treatment with methotrexate
Annals of the Rheumatic Diseases 2017;76:92.